|Creating the next generation of cancer treatments
Alexander Zukiwski, M.D.
Chief Executive Officer and Chief Medical Officer
Dr. Zukiwski is responsible for leading the clinical development and regulatory affairs teams supporting Arno's current and future pipeline of innovative cancer therapies. He has more than 15 years of experience in global oncology drug development and has supported the clinical evaluation and registration of many successful therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis® and Doxil®. Dr. Zukiwski was most recently Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc. where the organization he led was responsible for developing and implementing MedImmune's clinical research, medical affairs and safety strategies. Prior to joining MedImmune, Dr. Zukiwski held medical affairs and clinical development positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD), Centocor and Ortho Biotech, including serving as therapeutic area head for oncology and acting head of oncology research and development. Before joining Johnson & Johnson, Dr. Zukiwski held clinical oncology positions at Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. He received a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary and conducted post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas, M.D. Anderson Cancer Center.
Lawrence A. Kenyon
Chief Operating Officer and Chief Financial Officer
Mr. Kenyon was appointed to serve as Arno's Chief Financial Officer in February 2014, and named Chief Operating Officer in July 2014. Mr. Kenyon was most recently Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly-held company engaged in the development of oncology and anti-infective therapeutics, from December 2011 to March 2013. Prior to that, from December 2008 to July 2010, Mr. Kenyon was Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of Par Pharmaceutical Companies, Inc., a publicly-held generic and branded specialty pharmaceuticals company. Prior to joining Par, Mr. Kenyon was Chief Financial Officer and Secretary of Alfacell Corporation from January 2007 until February 2009; he also served at various times during this period as Alfacell's Executive Vice President, Chief Operating Officer, and President, and was a member of Alfacell's board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 until 2006. Mr. Kenyon holds a bachelor's degree in accounting from the University of Wisconsin-Whitewater and is a Certified Public Accountant.
Stefan Proniuk, Ph.D.
Chief Development Officer
Dr. Proniuk has over 16 years of experience in pharmaceutical product development. Since joining Arno in 2008, Dr. Proniuk has assumed roles of increasing responsibility. In his current position, he is responsible for the preclinical, chemical and pharmaceutical development of Arno's portfolio. Prior to joining Arno, Dr. Proniuk was at Neurocrine Biosciences where he was responsible for overseeing development programs from Phase I to III. His group was also responsible for the transition of discovery leads into development candidates of new chemical entities (NCEs). Prior to his work at Neurocrine, Dr. Proniuk worked at Cima Labs on the development and scale-up of fast dissolving tablet formulations. Throughout his career he has worked on multiple regulatory submissions and marketed products. Dr. Proniuk holds a Ph.D. degree in Pharmaceutical Sciences from the University of Arizona, an MBA with emphasis in Entrepreneurship from San Diego State University and a Diplom (FH) in Chemical Engineering from the University of Applied Sciences Isny, Germany.
David M. Jackson, Ph.D.
Vice President, Diagnostics
Dr. Jackson joined Arno as Vice President, Diagnostics in January 2014 and is responsible for managing various biomarker and companion diagnostic co-development partnerships in support of onapristone. He specializes in personalized medicine and companion diagnostics, including drug and diagnostic co-development, commercialization and investment, and has more than 16 years' experience with healthcare technology companies and healthcare investment firms with an emphasis on paradigm-changing technologies filling unmet market opportunities. Prior to joining Arno, Dr. Jackson was Vice President, Business Development at PrimeraDx, Inc., a molecular diagnostic manufacturer and companion diagnostic development partner, where he was responsible for corporate partnerships and contracts; in- and out-licensing; sell-side BD, design, execution and oversight of companion diagnostic partnership programs. Previously, he was Senior Director, Companion Diagnostics Partnerships at QIAGEN Manchester (formerly DxS, Ltd.), and since 2007, has worked as an independent development and commercialization consultant to bio and pharmaceutical drug developers, IVD manufacturers and specialized laboratories in the area of personalized medicine and companion diagnostics. Additionally, Dr. Jackson was a senior healthcare analyst covering molecular diagnostics and personalized medicine at ThinkPanmure and an analyst at Research Corporation Technologies, a healthcare-focused venture capital firm. Dr. Jackson earned a Ph.D. in Human Physiology & Medicine from Boston University School of Medicine and a B.S. in Biological Sciences from Texas A&M University.
Arno Therapeutics, Inc.